Back to Search
Start Over
"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
- Source :
-
International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2017 Feb 01; Vol. 12, pp. 487-494. Date of Electronic Publication: 2017 Feb 01 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- Many patients with chronic obstructive pulmonary disease (COPD) receive inhaled corticosteroids (ICSs) without a clear indication, and thus, the impact of ICS withdrawal on disease control is of great interest. DACCORD is a prospective, noninterventional 2-year study in the primary and secondary care throughout Germany. A subgroup of patients were taking ICS prior to entry - 1,022 patients continued to receive ICS for 2 years; physicians withdrew ICS on entry in 236 patients. Data from these two subgroups were analyzed to evaluate the impact of ICS withdrawal. Patients aged ≥40 years with COPD, initiating or changing COPD maintenance medication were recruited, excluding patients with asthma. Demographic and disease characteristics, prescribed COPD medication, COPD Assessment Test, exacerbations, and lung function were recorded. There were few differences in baseline characteristics; ICS withdrawn patients had shorter disease duration and better lung function, with 74.2% of ICS withdrawn patients not exacerbating, compared with 70.7% ICS-continued patients. During Year 1, exacerbation rates were 0.414 in the withdrawn group and 0.433 in the continued group. COPD Assessment Test total score improved from baseline in both groups. These data suggest that ICS withdrawal is possible with no increased risk of exacerbations in patients with COPD managed in the primary and secondary care.<br />Competing Interests: Disclosure CV reports personal fees from Almirall, AstraZeneca, Berlin-Chemie – Menarini, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, and Takeda, and grants and personal fees from Grifols. HW reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Novartis, and Takeda. RB reports personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, and Teva, and grants and personal fees from Boehringer Ingelheim, Novartis, and Roche. C-PC reports personal fees from Boehringer Ingelheim, Chiesi, GSK, Novartis, Takeda, and Berlin-Chemie. NSL is employed at Novartis Pharma GmbH, Nürnberg, Germany, the sponsor of the study. CM is employed at Novartis Pharma GmbH, Nürnberg, Germany, the sponsor of the study. PK reports personal fees from Novartis, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, and Takeda. The authors report no other conflicts of interest in this work.
- Subjects :
- Administration, Inhalation
Adrenal Cortex Hormones adverse effects
Adult
Aged
Bronchodilator Agents administration & dosage
Bronchodilator Agents adverse effects
Disease Progression
Drug Administration Schedule
Drug Combinations
Drug Therapy, Combination
Female
Germany
Humans
Lung physiopathology
Male
Middle Aged
Primary Health Care
Prospective Studies
Pulmonary Disease, Chronic Obstructive diagnosis
Pulmonary Disease, Chronic Obstructive physiopathology
Recovery of Function
Registries
Risk Factors
Secondary Care
Time Factors
Treatment Outcome
Adrenal Cortex Hormones administration & dosage
Lung drug effects
Pulmonary Disease, Chronic Obstructive drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1178-2005
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- International journal of chronic obstructive pulmonary disease
- Publication Type :
- Academic Journal
- Accession number :
- 28203072
- Full Text :
- https://doi.org/10.2147/COPD.S125616